Skip to main content
NCBI home page
Sarcoma logoLink to Sarcoma
. 1997 Dec;1(3-4):149–154. doi: 10.1080/13577149778236

A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma

Charles R Crawley 1, Ian R Judson 2,✉, Mark Verrill 2, Catherine Hill 2, Florence I Raynaud 3
PMCID: PMC2395367  PMID: 18521217

Abstract

Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS), following reports of substantial activity using this schedule of etoposide administration as first-line treatment in combination with ifosfamide.

Patients/method. This was an open phase I/II trial performed at a single institution in patients with metastatic or locally advanced STS who had failed first-line treatment with doxorubicin + ifosfamide combination chemotherapy or, less commonly, single-agent treatment with doxorubicin or ifosfamide. Etoposide was given as a continuous intravenous infusion over 72 h. The starting dose level was 200 mg m-2 day-1 × 3 escalating in 10% steps in cohorts of three patients until dose-limiting toxicity was encountered.

Results. Seventeen patients were treated, median age 47 years (range 26–71 years). No responses were seen in 16 assessable patients despite etoposide levels in the cotoxic range. The steady-state plasma concentration exceeded 8 μg ml−1 in all patients and in patients treated at ≥ 600 mg m −2 the mean steady-state level was 14.4 μg ml −1. The median event-free survival was 6 weeks (95% confidence interval (CI) 3.31–8.69) and the overall survival 16 weeks (95% CI 9.28–22.72). The maximum tolerated dose in this pretreated patient group was 200 mg mm-2 day-1 × 3. The dose-limiting toxicity was myelosuppression.

Discussion. Etoposide given by 72-h infusion is inactive as second-line chemotherapy in STS. It is associated with significant toxicity when given in these doses, in this patient group.

Full Text

The Full Text of this article is available as a PDF (505.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bramwell V. H., Mouridsen H. T., Santoro A., Blackledge G., Somers R., Verweij J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 1993;31 (Suppl 2):S180–S184. [PubMed] [Google Scholar]
  2. Clark P. I., Slevin M. L., Joel S. P., Osborne R. J., Talbot D. I., Johnson P. W., Reznek R., Masud T., Gregory W., Wrigley P. F. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol. 1994 Jul;12(7):1427–1435. doi: 10.1200/JCO.1994.12.7.1427. [DOI] [PubMed] [Google Scholar]
  3. Dombernowsky P., Buesa J., Pinedo H. M., Santoro A., Mouridsen H., Somers R., Bramwell V., Onsrud M., Rouesse J., Thomas D. VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol. 1987 May;23(5):579–580. doi: 10.1016/0277-5379(87)90324-5. [DOI] [PubMed] [Google Scholar]
  4. Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A. Chronic daily administration of oral etoposide--a phase I trial. J Clin Oncol. 1989 Mar;7(3):396–401. doi: 10.1200/JCO.1989.7.3.396. [DOI] [PubMed] [Google Scholar]
  5. Harvey V. J., Joel S. P., Johnston A., Slevin M. L. High-performance liquid chromatography of etoposide in plasma and urine. J Chromatogr. 1985 May 3;339(2):419–423. doi: 10.1016/s0378-4347(00)84674-5. [DOI] [PubMed] [Google Scholar]
  6. Joel S. The clinical pharmacology of etoposide: an update. Cancer Treat Rev. 1996 May;22(3):179–221. doi: 10.1016/s0305-7372(96)90002-x. [DOI] [PubMed] [Google Scholar]
  7. Kampe C. E., Lowenbraun S., Foster J., Rosen G. Oral etoposide in treatment of advanced refractory sarcomas. J Natl Cancer Inst. 1992 Dec 2;84(23):1836–1837. doi: 10.1093/jnci/84.23.1836. [DOI] [PubMed] [Google Scholar]
  8. Keizer H. J., Crowther D., Nielsen O. S., Oosterom A. T., Muguiro J. H., Pottelberghe C. V., Somers R., Tursz T. EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma. Sarcoma. 1997;1(2):99–101. doi: 10.1080/13577149778371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Licht J. D., Mazanet R., Loehrer P. J., Gonin R., Antman K. H. Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1994;34(1):79–80. doi: 10.1007/BF00686117. [DOI] [PubMed] [Google Scholar]
  10. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  11. Saeter G., Talle K., Solheim O. P. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer Chemother Pharmacol. 1995;36(2):172–175. doi: 10.1007/BF00689204. [DOI] [PubMed] [Google Scholar]
  12. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537–1545. doi: 10.1200/JCO.1995.13.7.1537. [DOI] [PubMed] [Google Scholar]
  13. Slevin M. L., Clark P. I., Joel S. P., Malik S., Osborne R. J., Gregory W. M., Lowe D. G., Reznek R. H., Wrigley P. F. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 1989 Sep;7(9):1333–1340. doi: 10.1200/JCO.1989.7.9.1333. [DOI] [PubMed] [Google Scholar]
  14. Thompson D. S., Hainsworth J. D., Hande K. R., Holzmer M. C., Greco F. A. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol. 1993 Jul;11(7):1322–1328. doi: 10.1200/JCO.1993.11.7.1322. [DOI] [PubMed] [Google Scholar]
  15. van Maanen J. M., Retèl J., de Vries J., Pinedo H. M. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst. 1988 Dec 7;80(19):1526–1533. doi: 10.1093/jnci/80.19.1526. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES